top of page
Search

AACR 2023, RSO-021, a first in class treatment

Florida, April 2023

Our Chief Science Officer, Dr. Brian Cunniff successfully presented key research at AACR 2023. Characterization of immune cell phenotypes in patient derived malignant pleural effusion treated with thiostrepton. Thiostrepton (TS) is a covalent inhibitor of mitochondrial Peroxiredoxin 3 (PRX3).




Comments


bottom of page